StockData
Spruce Biosciences, Inc. logo

Spruce Biosciences, Inc. (SPRB) stock

SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/30
$40.49−1.76 (-4.17%)

Close on Nov 17, 2026Market cap $116.37MP/E –Yield –

Spruce Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Spruce Biosciences's revenue for the twelve months ending Dec 31, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $0, down 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$4.91M-51.3%
FY2023Dec 31, 2023$10.09M–
FY2022Dec 31, 2022$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$0-100.0%
Q4 FY2024Dec 31, 2024$697.00K-75.9%
Q3 FY2024Sep 30, 2024$602.00K-80.4%
Q2 FY2024Jun 30, 2024$1.61M-25.6%
Q1 FY2024Mar 31, 2024$2.00M+1.9%
Q4 FY2023Dec 31, 2023$2.89M–
Q3 FY2023Sep 30, 2023$3.07M–
Q2 FY2023Jun 30, 2023$2.17M–
Q1 FY2023Mar 31, 2023$1.96M–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0–
Q1 FY2022Mar 31, 2022$0–

More Spruce Biosciences figures

See a number that looks wrong?